Physician profile
Mark Nunes
NPI 1063466027
$16,938.10
in general payments reported to CMS, 2019-2025
14 companies · $13K in 2025
The $13K reported for 2025 was more than what 87% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,903 · 2021: $750 · 2022: $31.06 · 2023: $26.37 · 2024: $22.02 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $1,588 · Consulting Fee: $750 · Travel and Lodging: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,175.00 |
| Food and Beverage | $1,588.06 |
| Consulting Fee | $750.00 |
| Travel and Lodging | $740.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $11,353.79 | 2025 | |
| Alexion Pharmaceuticals, INC. | $4,527.48 | 2019-2025 | Strensiq, Koselugo |
| Genzyme Corporation | $448.89 | 2022-2025 | |
| Pharming Healthcare, INC. | $153.32 | 2022-2025 | Joenja, Ruconest |
| Intrabio INC | $135.69 | 2025 | Aqneursa |
| Kedrion Biopharma, INC. | $128.38 | 2025 | Kedrab, Albuked, Rhogam Ultra-Filtered Plus |
| Takeda Pharmaceuticals U.S.A., INC. | $30.29 | 2025 | Advate |
| Biogen, INC. | $29.89 | 2025 | Spinraza |
| Springworks Therapeutics, INC. | $25.78 | 2025 | Gomekli |
| Genetix Biotherapeutics INC | $23.77 | 2025 | Lyfgenia |
| Medexus Pharma, INC. | $23.37 | 2025 | Ixinity |
| Novo Nordisk INC | $20.52 | 2025 | |
| Incyte Corporation | $19.86 | 2025 | Niktimvo |
| Sanofi US Services INC. | $17.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nunes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.